Table 3

Univariate and multivariate analyses of predictors for TNFi persistence and time to remission

Variable	TNFi persistence				Time to remission
	Univariate (n=497)		Multivariate (n=495)		Univariate (n=380)		Multivariate (n=379)
	HR	p Value	HR	p Value	HR	p Value	HR	p Value
Used multivariate analysis
Age, years	1.000	0.99	0.997	0.66	0.991	0.11	0.999	0.86
Sex, female vs male	1.279	0.13	1.256	0.18	0.744	0.046	0.826	0.21
Initial therapy, combination vs monotherapy	0.948	0.73	0.956	0.78	1.090	0.56	1.153	0.35
BMI, kg/m²	1.030	0.01	1.011	0.44	0.940	<0.001	0.955	<0.001
CDAI, point value	1.037	<0.001	1.027	0.001	0.944	0.002	0.964	0.052
mHAQ, point value	2.307	<0.001	1.585	0.049	0.257	<0.001	0.478	0.008
PsA duration, years	0.978	0.04	0.982	0.10	0.999	0.93	0.997	0.77
Alcohol use, yes vs no	0.913	0.57	1.013	0.97	1.265	0.11	0.953	0.76
Smoking, ever vs never			1.015	0.89			0.851	0.14
Univariate: demographics
Ethnicity, Hispanic vs non-Hispanic*	0.259	0.003			0.777	0.44
Univariate: disease activity or disability
Swollen joints, number	1.042	0.034			0.944	0.01
Tender joints, number	1.084	<0.001			0.912	0.01
Physician global assessment of disease activity, point value	1.016	0.001			0.978	0.001
Patient global assessment of disease activity, point value	1.011	0.001			0.976	<0.001
Physician global assessment of skin, point value*	1.006	0.12			0.981	<0.001
Patient global assessment of skin, point value*	1.011	0.001			0.991	0.04
Univariate: medical history and risk factors
History of coronary artery disease, yes vs no*	2.111	0.04			0.555	0.16
History of MTX, yes vs no	1.702	0.03			1.198	0.395
History of hypertension, yes vs no	1.267	0.18			0.505	0.001
History of diabetes, yes vs no	0.904	0.75			0.496	0.03

Variables presented in this table were either statistically significant in at least one univariate analysis or included in a multivariate analysis. Complete univariate and multivariate analysis tables (including 95% CIs for HRs) by analysis are presented in the online supplementary appendices tables S1 and S2. In the TNFi persistence analysis, an HR >1 indicates increased risk of therapy switch and, therefore, shorter TNFi persistence. In the time to remission analysis, an HR >1 indicates increased risk of achieving remission and, therefore, achieving remission faster. In the time to loss of remission after therapy switch analysis, an HR >1 indicates increased risk of losing remission and, therefore, shorter time to loss of remission.
*Values not recorded for patients enrolled early in the study. Updates to the enrolment form added variables.
BMI, body mass index; CDAI, Clinical Disease Activity Index; mHAQ, modified Health Assessment Questionnaire; MTX, methotrexate; NA, (data) not available; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor.